PDCD1 and melanoma: IRAEs are less frequent in anti-PD-1 treated patients than in those treated with CTLA-4 blockade (13.3% as opposed to 19.9% in anti-CTLA-4 treated patients) leading to approval of anti-PD-1 treatment as first line for advanced melanoma in the USA and the EU[2, 98].